Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 39 articles:
HTML format

Single Articles

    January 2022
  1. CALLAHAN MK, Chapman PB
    PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2102801. doi: 10.1200/JCO.21.02801.

  2. DUMMER R, Long GV, Robert C, Tawbi HA, et al
    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2101601. doi: 10.1200/JCO.21.01601.
    PubMed     Abstract available

    December 2021
  3. POSTOW MA, Goldman DA, Shoushtari AN, Betof Warner A, et al
    Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570.
    PubMed     Abstract available

    November 2021
  4. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229.
    PubMed     Abstract available

    August 2021
  5. ANDTBACKA RHI, Curti B, Daniels GA, Hallmeyer S, et al
    Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    J Clin Oncol. 2021 Aug 31:JCO2003246. doi: 10.1200/JCO.20.03246.
    PubMed     Abstract available

    July 2021
  6. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed     Abstract available

    June 2021
  7. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.

    Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
    J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.

    May 2021
  9. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available

  10. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available

    February 2021
  11. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available

    January 2021
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.

  13. HINDIE E
    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.

  14. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available

  15. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available

  16. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.

    October 2020
  17. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available

    September 2020
  18. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available

  19. EGGERMONT AMM, Blank CU, Mandala M, Long GV, et al
    Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2002110. doi: 10.1200/JCO.20.02110.
    PubMed     Abstract available

    July 2020
  20. KARAKOUSIS G, Sondak VK, Zager JS
    Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas.
    J Clin Oncol. 2020 Jul 23:JCO2001686. doi: 10.1200/JCO.20.01686.

  21. OLOFSSON BAGGE R, Kicinski M, Faries MB, Gyorki DE, et al
    Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
    J Clin Oncol. 2020 Jul 23:JCO2001680. doi: 10.1200/JCO.20.01680.

  22. HINDIE E
    Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim.
    J Clin Oncol. 2020 Jul 23:JCO2001199. doi: 10.1200/JCO.20.01199.

    June 2020
  23. LO SN, Ma J, Scolyer RA, Haydu LE, et al
    Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
    J Clin Oncol. 2020 Jun 12:JCO1902362. doi: 10.1200/JCO.19.02362.
    PubMed     Abstract available

  24. GARBE C, Keim U, Suciu S, Amaral T, et al
    Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
    J Clin Oncol. 2020 Jun 12:JCO1903034. doi: 10.1200/JCO.19.03034.
    PubMed     Abstract available

    May 2020
    Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma.
    J Clin Oncol. 2020 May 28:JCO2001121. doi: 10.1200/JCO.20.01121.

    April 2020
  26. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available

    March 2020
  27. SETH R, Messersmith H, Kaur V, Kirkwood JM, et al
    Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198.
    PubMed     Abstract available

  28. MAURICHI A, Miceli R, Eriksson H, Newton-Bishop J, et al
    Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.
    J Clin Oncol. 2020 Mar 13:JCO1901902. doi: 10.1200/JCO.19.01902.
    PubMed     Abstract available

    February 2020
    Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
    J Clin Oncol. 2020 Feb 25:JCO2000136. doi: 10.1200/JCO.20.00136.

  30. BETOF WARNER A, Palmer JS, Shoushtari AN, Goldman DA, et al
    Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
    J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464.
    PubMed     Abstract available

    January 2020
  31. HAYDU LE, Lo SN, McQuade JL, Amaria RN, et al
    Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
    J Clin Oncol. 2020 Jan 28:JCO1901508. doi: 10.1200/JCO.19.01508.
    PubMed     Abstract available

    December 2019
  32. BETOF WARNER A, Postow MA
    Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.
    J Clin Oncol. 2019 Dec 27:JCO1902988. doi: 10.1200/JCO.19.02988.

  33. TARHINI AA, Lee SJ, Hodi FS, Rao UNM, et al
    Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    J Clin Oncol. 2019 Dec 27:JCO1901381. doi: 10.1200/JCO.19.01381.
    PubMed     Abstract available

    October 2019
  34. MENZER C, Menzies AM, Carlino MS, Reijers I, et al
    Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
    J Clin Oncol. 2019 Oct 3:JCO1900489. doi: 10.1200/JCO.19.00489.
    PubMed     Abstract available

    September 2019
  35. LEITER U, Stadler R, Mauch C, Hohenberger W, et al
    Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    J Clin Oncol. 2019 Sep 26:JCO1802306. doi: 10.1200/JCO.18.02306.
    PubMed     Abstract available

  36. HONG AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, et al
    Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 25:JCO1901414. doi: 10.1200/JCO.19.01414.
    PubMed     Abstract available

    May 2019
  37. LONG GV, Dummer R, Schadendorf D, Santinami M, et al
    Reply to E. Hindie and K.R. Hess.
    J Clin Oncol. 2019;37:1356-1358.

    April 2019
  38. KLUGER HM, Margolin KA, Davies MA, Long GV, et al
    Reply to A. Shinde et al.
    J Clin Oncol. 2019;37:1031-1032.

  39. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.